Sorrento Acquires the Sofusa™ Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics
Pioneered by inventor Dr.
“Sofusa technology allows pharmacological targeting of the lymphatics allowing new treatment strategies for cancer and chronic inflammatory conditions,” said Dr.
“Delivering higher drug concentrations via the lymphatics could provide more direct and sustained exposure to therapeutic targets known to modulate immune responses. We believe this has the potential to result in an improved safety and efficacy profile for checkpoint inhibitors and anti-inflammatory agents. Sorrento is now well positioned to becoming a leader in the immunotherapy field and fulfill our mission to develop best-in-class antibodies for patients,” said Dr.
"We are impressed with Sofusa’s data, where in preclinical models using immunomodulatory antibodies, the Sofusa system consistently demonstrated significantly higher lymphatic levels compared to other delivery routes while exhibiting equipotent or better therapeutic activity. We believe that the Sofusa technology could be a game changer for the delivery of our immunotherapies, including checkpoint inhibitors, biobetter antibodies, and other I-O antibodies,” said Dr. Henry Ji, President and CEO.
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and clinical stage oncolytic virus (“Seprehvir®”).
Sorrento's commitment to life-enhancing therapies for cancer patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule in Resiniferatoxin (“RTX”) and ZTlido. RTX is completing a phase IB trial in terminal cancer patients. ZTlido was approved by US FDA on
For more information visit www.sorrentotherapeutics.com
1 Kwon S, Velasquez CF, Ross, RF, Hwu, WJ, and EM Sevick-Muraca, “Anti-tumoral effects of novel lymphatic delivery of anti-CTLA4 in a metastatic murine breast cancer model”
Media and Investor Relations
Source: Sorrento Therapeutics, Inc.